Interneuron/Warner-Lambert pagoclone

Warner-Lambert licenses anxiolytic pagoclone for the treatment of panic and generalized anxiety disorders from Interneuron. Under the agreement, Interneuron stands to receive $73.8 mil. in up-front and milestone payments. A portion of those payments will be given to Aventis based on Interneuron's 1994 licensing of pagoclone from Rhone-Poulenc Rorer